



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN:L24294TN1995PLCO30698

Date: April 08, 2024.

To

The Manager Listing Department, BSE Limited, P J Towers, Dalal Street, Mumbai - 400001.	The Manager Listing Department, National Stock Exchange of India, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051.
---	--

Dear Sir/Madam,

Sub: Disclosures under Regulation 31 (4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Ref: Scrip Code : 532989; Symbol : BAFNAPH; ISIN : INE878I01022

Please find enclosed herewith the annual disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011 for the year ended on 31st March 2024 received from Promoters of the Company.

We request you to take the information on record.

Thanking You.

For **Bafna Pharmaceuticals Limited**

SHANMUGAM HEMALATHA

Whole-Time Director

(DIN: 02714329)

MAHAVEER CHAND BAFNA

Address: No.40B, Thambusamy Road,
Kilpauk, Chennai - 600010

Date: 06.04.2024

To
The Manager,
Listing Department,
BSE Limited,
P J Towers,
Dalal Street, Mumbai - 400001.

The Manager,
Listing Department,
National Stock Exchange of India,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051.

Dear Sir,

**Sub: Disclosures under Regulation 31 (4) of SEBI (Substantial Acquisition of Shares
& Takeover) Regulations, 2011**

Scrip Code : 532989 Symbol: BAFNAPH ISIN : INE878I01022

As per Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulation, 2011, I, Mahaveer Chand Bafna, being the Promoter of Bafna Pharmaceuticals Limited ("The Company"), hereby declare on behalf of the Promoters, Promoter Group & Person Acting in Concert that we have not made any encumbrance of shares of the Company, directly or indirectly, other than those already disclosed, if any, during the financial year ended March 31, 2024.

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you.

Yours Faithfully,



MAHAVEER CHAND BAFNA

(For and on behalf of Promoter & Promoter Group)

CC:

- 1) Audit Committee - Bafna Pharmaceuticals Limited
- 2) Company Secretary - Bafna Pharmaceuticals Limited

SRJR LIFESCIENCES LLP

LLPIN: AAR-4517

ILABS CENTRE BUILDING NO.3, , NO.18, SOFTWARE UNITS LAYOUT, MADHAPUR,
HYDERABAD, TELANGANA - 500 081

Date: 5th April 2024

To
General Manager
Listing Department
BSE Limited
P J Towers, Dalal Street Fort
Mumbai- 400 001

To
General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051

To
Company Secretary
Bafna Pharmaceuticals Ltd
Bafna Towers, 299, Thambu Chetty Street,
Chennai, Tamil Nadu, 600001

Dear Sir,

Sub.: - Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Symbol : BAFNAPH
Security code : 532989
ISIN : INE878I01022

As per Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we, SRJR LIFESCIENCES LLP being the promoter of Bafna Pharmaceuticals Ltd ("Company"), hereby declare and confirm that we have not made any encumbrance over the shares held by us in the Company, directly or indirectly, during the financial year ended March 31, 2024.

We request you to take on record the above information and acknowledge the receipt of the same.

Thanking You,

For SRJR LIFESCIENCES LLP


Upendar Mekala Reddy
Designated Partner
DIN:08898174



CC: Audit Committee
Bafna Pharmaceuticals Ltd

Ph.: +91 40 4048 4444, Email ID: accounts@ilabsgroup.com